Does Prolonged IV Amikacin Therapy Improve Outcomes in M Abscessus?
What is the efficacy of ongoing treatment of Mycobacterium abscessus pulmonary disease with IV amikacin in patients with persistent culture positivity?
Lung Disease
Lung Abnormalities Identified on Hp-XeMRI in Nonhospitalized Long COVID Patients
Specialized imaging shows that posthospitalized COVID-19 patients and nonhospitalized patients with post-COVID-19 condition have lung abnormalities.
Long-COVID Lung Disease: Researchers Characterize 3 Phenotypes
Can long-COVID lung diseases be better understood and classified via analysis of abnormalities seen on transbronchial lung cryobiopsies?
Clinical Trial Compares Glassia, Prolastin for Alpha1-Antitrypsin Deficiency
A clinical trial compared the efficacy of 2 alpha1-proteinase inhibitors, Glassia and Prolastin, for the treatment of patients with alpha1-antitrypsin deficiency.
R mucilaginosa in Lower Airways Mitigates Inflammation in Chronic Lung Disorders
Researchers assessed the immunomodulatory activity of bacteria in the lung microbiota, which led to a closer analysis on R mucilaginosa’s anti-inflammatory effect.
Exposure to Inhaled Corticosteroids Increases Risk for Nontuberculous Mycobacterial Lung Disease
Researchers conducted a meta-analysis to assess the risk for nontuberculous mycobacterial lung disease in patients who use inhaled corticosteroids.
Effect of Metabolic Syndrome on WTC-Lung Disease Risk Examined
Firefighters who were on active duty on Sept. 11, 2001 (9/11) may be able to reduce their risk for World Trade Center-Lung Injury (WTC-LI).
What Affects Prescription Adherence of Patients With Obstructive Lung Disease?
This studied focused on primary prescription adherence for obstructive lung diseases among adult patients in primary care over a 3-year period.
FDA: NJ Company Must Stop Selling Unapproved Flavored Vaping Products
Eonsmoke LLC has been ordered to halt illegal sales of 100 unapproved flavored vaping products in the United States.
Mesothelioma Progression-Free Survival Does Not Improve With Anetumab Ravtansine
Median overall survival increased from 10.1 months with anetumab ravtansine to 11.6 months with vinorelbine.
- Loading...
Loading...
Next post in Treatments
Loading... 
Loading...